Stevanato Group Secures €130 Million ESG-Linked Financing From BNL BNP Paribas and Cassa Depositi e Prestiti to Support Sustainable Global Growth

Stevanato Group S.p.A. (NYSE: STVN), a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced two separate agreements with BNL BNP Paribas and Cassa Depositi e Prestiti Group (CDP) to obtain ESG-linked funds to support its ongoing global expansion.